Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | RAF1 | P04049 | 2/20 | 0.37 |
| ▸ | ACACB | O00763 | 6/20 | 0.37 |
| ▸ | BCHE | P06276 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.34 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.34 |
| ▸ | PDE5A | O76074 | 2/20 | 0.33 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.33 |
| ▸ | CACNG8 | Q8WXS5 | 1/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.33 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.33 |
| ▸ | HTR1B | P28222 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23523958 | 0.82 | NR1H4 (0.50) | CNR1CNR2MAPT | |
| SCHEMBL30355837 | 0.82 | NR1H4 (0.50) | CNR1CNR2MAPT | |
| SCHEMBL25856896 | 0.80 | MAPT (0.45) | CNR1CNR2MAPT | |
| SCHEMBL25856843 | 0.76 | CNR1 (0.40) | CNR1CNR2GRIA1CACNG8MAPT | |
| SCHEMBL25856856 | 0.76 | NPC1 (0.43) | CNR1CNR2ACACBMAPT | |
| SCHEMBL25856668 | 0.76 | CNR1 (0.40) | CNR1CNR2ACACBGRIA1CACNG8 | |
| SCHEMBL25856939 | 0.75 | CNR1 (0.40) | CNR1CNR2ACACBMAPT | |
| SCHEMBL25856972 | 0.75 | CNR1 (0.40) | CNR1CNR2GRIA1CACNG8MAPT | |
| SCHEMBL25857476 | 0.74 | CNR1 (0.39) | CNR1CNR2ACACBMAPT | |
| SCHEMBL23558451 | 0.73 | NR1H4 (0.52) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234946-A1 | COMPOUNDS FOR MODULATING S1P1 ACTIVITY AND METHODS OF USING THE SAME | TREVENA, INC. | 2023-07-27 | — | — | US | disclosed |
| US-20230234946-A1 | COMPOUNDS FOR MODULATING S1P1 ACTIVITY AND METHODS OF USING THE SAME | TREVENA, INC. | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234946-A1 | COMPOUNDS FOR MODULATING S1P1 ACTIVITY AND METHODS OF USING THE SAME | S1PR1, S1PR2, S1PR3 | CNR1 20/4885CNR2 38/4885RAF1 1120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.